Compliance Matters Should Be Exempt From Coverage Requests – Medtronic
This article was originally published in The Gray Sheet
Executive Summary
CMS' consideration of recalls associated with Medtronic's 508 and Paradigm insulin infusion pumps is "inappropriate" in the context of deciding whether to alter national coverage criteria for insulin pump therapy, the firm contends